ENTITLED, An Act to revise the controlled substance schedule and to declare an emergency.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF SOUTH DAKOTA:
Section 1. That § 34-20B-1 be amended to read as follows:
34-20B-1. Terms as used in this chapter mean:
(1) "Administer," to deliver a controlled drug or substance to the ultimate user or human
research subject by injection, inhalation, or ingestion, or by any other means;
(2) "Agent," an authorized person who acts on behalf of or at the direction of a manufacturer,
distributor, or dispenser and includes a common or contract carrier, public warehouseman,
or employee thereof;
(3) "Control," to add, remove, or change the placement of a drug, substance, or immediate
precursor under §§ 34-20B-27 and 34-20B-28;
(4) "Counterfeit substance," a controlled drug or substance which, or the container or labeling
of which, without authorization, bears the trademark, trade name, or other identifying
mark, imprint, number, or device, or any likeness thereof, of a manufacturer, distributor,
or dispenser other than the person or persons who manufactured, distributed, or dispensed
such substance and which thereby falsely purports or is represented to be the product of,
or to have been distributed by, such other manufacturer, distributor, or dispenser;
(5) "Deliver" or "delivery," the actual, constructive, or attempted transfer of a controlled drug,
substance, or marijuana whether or not there exists an agency relationship;
(6) "Department," the Department of Health created by chapter 1-43;
(7) "Dispense," to deliver a controlled drug or substance to the ultimate user or human
research subject by or pursuant to the lawful order of a practitioner, including the
prescribing, administering, packaging, labeling, or compounding necessary to prepare the
substance for such delivery, and a dispenser is one who dispenses;
(8) "Distribute," to deliver a controlled drug, substance, or marijuana. A distributor is a
person who delivers a controlled drug, substance, or marijuana;
(9) "Hashish," the resin extracted from any part of any plant of the genus cannabis, commonly
known as the marijuana plant;
(10) "Imprisonment," imprisonment in the state penitentiary unless the penalty specifically
provides for imprisonment in the county jail;
(11) "Manufacture," the production, preparation, propagation, compounding, or processing of
a controlled drug or substance, either directly or indirectly by extraction from substances
of natural origin, or independently by means of chemical synthesis or by a combination
of extraction and chemical synthesis. A manufacturer includes any person who packages,
repackages, or labels any container of any controlled drug or substance, except
practitioners who dispense or compound prescription orders for delivery to the ultimate
consumer;
(12) "Marijuana," all parts of any plant of the genus cannabis, whether growing or not; the
seeds thereof; and every compound, manufacture, salt, derivative, mixture, or preparation
of such plant or its seeds; but does not include fiber produced from the mature stalks of
such plant, or oil or cake made from the seeds of such plant, or the resin when extracted
from any part of such plant;
(13) "Narcotic drug," any of the following, whether produced directly or indirectly by
extraction from substances of vegetable origin or independently by means of chemical
synthesis, or by a combination of extraction and chemical synthesis:
(a) Opium, coca leaves, and opiates;
(b) A compound, manufacture, salt, derivative, or preparation of opium, coca leaves,
or opiates;
(c) A substance (and any compound, manufacture, salt, derivative, or preparation
thereof) which is chemically identical with any of the substances referred to in
subsections (a) and (b) of this subdivision;
except that the term, narcotic drug, as used in this chapter does not include decocainized
coca leaves or extracts of coca leaves, which extracts do not contain cocaine or ecgonine;
(14) "Opiate," any controlled drug or substance having an addiction-sustaining liability similar
to morphine or being capable of conversion into a drug having such addiction-forming or
addiction-sustaining liability;
(15) "Opium poppy," the plant of the species papaver somniferum L., except the seeds thereof;
(16) "Person," any corporation, association, limited liability company, partnership or one or
more individuals;
(17) "Poppy straw," all parts, except the seeds, of the opium poppy, after mowing;
(18) "Practitioner," a doctor of medicine, osteopathy, podiatry, optometry, dentistry, or
veterinary medicine licensed to practice their profession, or pharmacists licensed to
practice their profession; physician assistants certified to practice their profession; nurse
practitioners and nurse midwives licensed to practice their profession; government
employees acting within the scope of their employment; and persons permitted by
certificates issued by the department to distribute, dispense, conduct research with respect
to, or administer a substance controlled by this chapter;
(18A) "Prescribe," an order of a practitioner for a controlled drug or substance.
(19) "Production," the manufacture, planting, cultivation, growing, or harvesting of a
controlled drug or substance;
(20) "State," the State of South Dakota;
(21) "Ultimate user," a person who lawfully possesses a controlled drug or substance for
personal use or for the use of a member of the person's household or for administration
to an animal owned by the person or by a member of the person's household;
(22) "Controlled substance analogue," any of the following:
(a) A substance that differs in its chemical structure to a controlled substance listed in
or added to the schedule designated in schedule I or II only by substituting one or
more hydrogens with halogens or by substituting one halogen with a different
halogen; or
(b) A substance that is an alkyl homolog of a controlled substance listed in or added
to schedule I or II; or
(c) A substance intended for human consumption; and
(i) The chemical structure of which is substantially similar to the chemical
structure of a controlled substance in schedule I or II;
(ii) Which has a stimulant, depressant, or hallucinogenic effect on the central
nervous system that is substantially similar to or greater than the stimulant,
depressant, or hallucinogenic effect on the central nervous system of a
controlled substance in schedule I or II; or
(iii) With respect to a particular person, which such person represents or intends
to have a stimulant, depressant, or hallucinogenic effect on the central
nervous system that is substantially similar to or greater than the stimulant,
depressant, or hallucinogenic effect on the central nervous system of a
controlled substance in schedule I or II;
However, the term, controlled substance analogue, does not include a controlled substance
or any substance for which there is an approved new drug application.
Section 2. That chapter 34-20B be amended by adding thereto a NEW SECTION to read as
follows:
A controlled substance analogue shall be treated as a controlled substance in schedule I.
Section 3. That § 34-20B-4.1 be amended to read as follows:
34-20B-4.1. An anabolic steroid is any drug or hormonal substance, chemically and
pharmacologically related to testosterone, other than estrogens, progestins, and corticosteroids, that
promotes muscle growth and includes:
(1) Androstanediol:
(a) 3.,17.-dihydroxy-5a-androstane;
(b) 3.,17.-dihydroxy-5a-androstane;
(2) Androstanedione (5.-androstan-3,17-dione);
(3) Androstenediol:
(a) 1-androstenediol (3.,17.-dihydroxy-5.- androst-1-ene);
(b) 1-androstenediol (3.,17.-dihydroxy-5.- androst-1-ene);
(c) 4-androstenediol (3.,17.-dihydroxy-androst-4-ene);
(d) 5-androstenediol (3.,17.-dihydroxy-androst-5-ene);
(4) Androstenedione:
(a) 1-androstenedione ([5.]-androst-1-en-3,17-dione);
(b) 4-androstenedione (androst-4-en-3,17-dione);
(c) 5-androstenedione (androst-5-en-3,17-dione);
(5) Bolasterone (7.,17.-dimethyl-17.-hydroxyandrost-4-en-3-one);
(6) Boldenone (17.-hydroxyandrost-1,4,-diene-3-one);
(7) Calusterone (7.,17.-dimethyl-17.-hydroxyandrost-4-en-3-one);
(8) Clostebol (4-chloro-17.-hydroxyandrost-4-en-3-one);
(9) Dehydrochloromethyltestosterone (4-chloro-17.-hydroxy-17.- methyl-androst-1,4-dien-3-one);
(10) .1-dihydrotestosterone (a.k.a. '1-testosterone') (17.-hydroxy-5.-androst-1-en-3-one);
(11) 4-dihydrotestosterone (17.-hydroxy-androstan-3-one);
(12) Drostanolone (17.-hydroxy-2.-methyl-5.-androstan-3-one);
(13) Ethylestrenol (17.-ethyl-17.-hydroxyestr-4-ene);
(14) Fluoxymesterone (9-fluoro-17.-methyl-11.,17.-dihydroxyandrost-4-en-3-one);
(15) Formebolone (2-formyl-17.-methyl-11.,17.-dihydroxyandrost-1,4-dien-3-one);
(16) Furazabol (17.-methyl-17.-hydroxyandrostano[2,3-c]- furazan);
(17) 13.-ethyl-17.-hydroxygon-4-en-3-one;
(18) 4-hydroxytestosterone (4,17.-dihydroxy-androst-4-en-3-one);
(19) 4-hydroxy-19-nortestosterone (4,17.-dihydroxy-estr-4-en-3-one);
(20) Mestanolone (17.-methyl-17.-hydroxy- 5.-androstan-3-one);
(21) Mesterolone (1.-methyl-17.-hydroxy-[ 5.]-androstan-3-one);
(22) Methandienone (17.-methyl-17.-hydroxyandrost-1,4-dien- 3-one);
(23) Methandriol (17.-methyl-3.,17.- dihydroxyandrost-5-ene);
(24) Methenolone (1-methyl-17.-hydroxy-5.-androst-1-en-3- one);
(25) 17.-methyl-3.,17.-dihydroxy-5a-androstane;
(26) 17.-methyl-3.,17.-dihydroxy-5a-androstane;
(27) 17.-methyl-3.,17.-dihydroxyandrost-4-ene;
(28) 17.-methyl-4-hydroxynandrolone (17.-methyl-4-hydroxy- 17.-hydroxyestr-4-en-3-one);
(29) Methyldienolone (17.-methyl-17.-hydroxyestra-4,9(10)- dien-3-one);
(30) Methyltrienolone (17.-methyl-17.-hydroxyestra-4,9-11- trien-3-one);
(31) Methyltestosterone (17.-methyl-17.-hydroxyandrost-4-en-3-one);
(32) Mibolerone (7.,17.-dimethyl-17.- hydroxyestr-4-en-3-one);
(33) 17.-methyl-.1-dihydrotestosterone (17b.-hydroxy-17.-methyl-5.- androst-1-en-3-one)
(also known as 17-.-methyl-1-testosterone);
(34) Nandrolone (17.-hydroxyestr-4-en-3-one);
(35) Norandrostenediol:
(a) 19-nor-4-androstenediol (3.,17.-dihydroxyestr-4-ene);
(b) 19-nor-4-androstenediol (3.,17.-dihydroxyestr-4-ene);
(c) 19-nor-5-androstenediol (3.,17.-dihydroxyestr-5-ene);
(d) 19-nor-5-androstenediol (3.,17.-dihydroxyestr-5-ene);
(36) Norandrostenedione:
(a) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
(b) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
(37) Norbolethone (13.,17.-diethyl-17.-hydroxygon-4-en-3-one);
(38) Norclostebol (4-chloro-17.-hydroxyestr-4-en-3-one);
(39) Norethandrolone (17.-ethyl-17.-hydroxyestr-4-en-3-one);
(40) Normethandrolone (17.-methyl-17.-hydroxyestr-4-en-3-one);
(41) Oxandrolone (17.-methyl-17.-hydroxy-2-oxa-[5.]-androstan-3-one);
(42) Oxymesterone (17.-methyl-4,17.-dihydroxyandrost-4-en- 3-one);
(43) Oxymetholone (17.-methyl-2-hydroxymethylene-17.- hydroxy-[5.]-androstan-3-one);
(44) Stanozolol (17.-methyl-17.-hydroxy-[5.]-androst-2-eno[3,2-c]-pyrazole);
(45) Stenbolone (17.-hydroxy-2-methyl-[5.]-androst-1-en-3-one);
(46) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
(47) Testosterone (17.-hydroxyandrost-4-en-3-one);
(48) Tetrahydrogestrinone (13.,17.-diethyl-17.-hydroxygon-4,9,11-trien-3-one);
(49) Trenbolone (17.-hydroxyestr-4,9,11-trien-3-one);
(50) Boldione (androsta-1,4-diene-3,17-dione);
(51) Desoxymethyltestosterone (17.-methyl-5.-androst-2-en-17.-ol) (also known as madol);
(52) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
(53) Prostanozol (17.-hydroxy-5.-androstano[3,2-c]pyrazole);
(54) Methasterone (2.,17.-dimethyl-5.-androstan-17.-ol-3-one); and
(55) Any salt, ester, or ether of a drug or substance described or listed in this section, if that
salt, ester, or ether promotes muscle growth.
The term, anabolic steroid, as defined in this section, does not include an anabolic steroid which
is expressly intended for administration through implants to cattle or other nonhuman species.
However, if any person prescribes, dispenses, or distributes such a steroid for human use, the person
shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the
meaning of this section.
Section 4. That § 34-20B-14 be amended to read as follows:
34-20B-14. Any material, compound, mixture, or preparation which contains any quantity of the
following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in
Schedule I, unless specifically excepted, whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
(1) Bufotenine;
(2) Diethyltryptamine (DET);
(3) Dimethyltryptamine (DMT);
(4) 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT);
(5) 5-methoxy-3, 4-methylenedioxy amphetamine;
(6) 4-bromo-2, 5-dimethoxyamphetamine;
(7) 4-methoxyamphetamine;
(8) 4-methoxymethamphetamine;
(9) 4-methyl-2, 5-dimethoxyamphetamine;
(10) Hashish and hash oil;
(11) Ibogaine;
(12) Lysergic acid diethylamide;
(13) Mescaline;
(14) N-ethyl-3-piperidyl benzilate;
(15) N-methyl-3-piperidyl benzilate;
(16) 1-(-(2-thienyl)cyclohexyl) piperdine;
(17) Peyote, except that when used as a sacramental in services of the Native American church
in a natural state which is unaltered except for drying or curing and cutting or slicing, it
is hereby excepted.;
(18) Psilocybin;
(19) Psilocyn;
(20) Tetrahydrocannabinol, other than that which occurs in marijuana in its natural and
unaltered state, including any compound, except nabilone or compounds listed under a
different schedule, structurally derived from 6,6' dimethyl-benzo[c]chromene by
substitution at the 3-position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl
groups, whether or not the compound is further modified in any of the following ways:
(a) By partial to complete saturation of the C-ring; or
(b) By substitution at the 1-position with a hydroxyl or methoxy group; or
(c) By substitution at the 9-position with a hydroxyl, methyl, or methylhydoxyl group;
or
(d) By modification of the possible 3-alkyl group with a 1,1' dimethyl moiety, a 1,1'
cyclic moiety, an internal methylene group, an internal acetylene group, or a
terminal halide, cyano, azido, or dimethylcarboxamido group.
Some trade and other names: JWH-051; JWH-057; JWH-133; JWH-359; HHC;
AM-087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211;
HU-243; HU-336;
(21) 3, 4, 5-trimethoxy amphetamine;
(22) 3, 4-methylenedioxy amphetamine;
(23) 3-methoxyamphetamine;
(24) 2, 5-dimethoxyamphetamine;
(25) 2-methoxyamphetamine;
(26) 2-methoxymethamphetamine;
(27) 3-methoxymethamphetamine;
(28) Phencyclidine;
(29) 3, 4-methylenedioxymethamphetamine (MDMA);
(30) 3, 4-methylenedioxy-N-ethylamphetamine;
(31) N-hydroxy-3, 4-methylenedioxyamphetamine;
(32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline);
(33) 2,5 Dimethoxy-4-ethylamphetamine;
(34) N,N-Dimethylamphetamine;
(35) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine;
(36) Aminorex;
(37) Cathinone and other variations, defined as any compound, material, mixture, preparation
or other product unless listed in another schedule or an approved FDA drug (e.g.
buproprion, pyrovalerone), structurally derived from 2-aminopropan-1-one by substitution
at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not
the compound is further modified in any of the following ways:
(a) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the
ring system by one or more other univalent substitutents;
(b) By substitution at the 3-position with an acyclic alkyl substituent;
(c) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a cyclic
structure.
Some trade or other names: methcathinone, 4-methyl-N-methylcathinone (mephedrone);
3,4-methylenedioxy-N-methylcathinone (methylone); 3,4-methylenedioxypyrovalerone
(MDPV); Naphthylpyrovalerone (naphyrone); 4-flouromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk-PMMA); Ethcathinone (N-Ethylcathinone); 3,4-methylenedioxyethcathinone (ethylone); Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N-dimethylcathinone (metamfepramone); Alpha-pyrrolidinopropiophenone (alpha-PPP); 4-methoxy-alpha-pyrrolidinopropiophenone
(MOPPP); 3,4-methylenedioxyalphapyrrolidinopropiophenone (MDPPP); Alpha-pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4'-Methyl-alpha-pyrrolidinobutiophenone (MPBP); Methyl-.-pyrrolindinopropiophenone (MPPP);
Methyl-.-pyrrolidino-hexanophenone (MPHP); Buphedrone; Methyl-N-ethylcathinone;
Pentedrone; Dimethylmethcathinone (DMMC); Dimethylethcathinone (DMEC);
Methylenedioxymethcathinone (MDMC); Pentylone; Ethylethcathinone;
Ethylmethcathinone; Fluoroethcathinone; methyl-alpha-pyrrolidinobutiophenone
(MPBP); Methylecathinone (MEC); Methylenedioxy-alpha-pyrrolidinobutiophenone
(MDPBP); Methoxymethcathinone (MOMC); Methylbuphedrone (MBP); Benzedrone (4-MBC); Dibutylone (DMBDB); Dimethylone (MDDMA); Diethylcathinone; Eutylone
(EBDB); N-ethyl-N-Methylcathinone; N-ethylbuphedrone;
(38) 2,5-Dimethoxy-4-ethylamphetamine (DOET);
(39) Alpha-ethyltryptamine;
(40) 4-Bromo-2,5-dimethoxy phenethylamine;
(41) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);
(42) 1-(3-trifluoromethylphenyl) piperazine (TFMPP);
(43) Alpha-methyltryptamine (AMT);
(44) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(45) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
(46) Synthetic cannabinoids. Any material, compound, mixture, or preparation that is not listed
as a controlled substance in another schedule, is not an FDA-approved drug, and contains
any quantity of the following substances, their salts, isomers (whether optical, positional,
or geometric), homologues, and salts of isomers and homologues, unless specifically
excepted, whenever the existence of these salts, isomers, homologues, and salts of
isomers and homologues is possible within the specific chemical designation:
(a) Naphthoylindoles. Any compound containing a 3-(1-naphthoyl)indole structure
with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinhyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not
further substituted in the indole ring to any extent and whether or not substituted
in the naphthyl ring to any extent.
Some trade or other names: JWH-015; 1-pentyl-3-(1-naphthoyl)indole (JWH-018);
1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398; 1-pentyl-3-(1-naphthoyl)indole
(AM-678); 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201); WIN 55-212;
JWH-004; JWH-007; JWH-009; JWH-011; JWH-016; JWH-020; JWH-022; JWH-046; JWH-047; JWH-048; JWH-049; JWH-050; JWH-070; JWH-071; JWH_072;
JWH-076; JWH-079; JWH-080; JWH-082; JWH-094; JWH-096; JWH-098; JWH-116; JWH-120; JWH-148; JWH-149; JWH-164; JWH-166; JWH-180; JWH-181;
JWH-182; JWH-189; JWH-193; JWH-198; JWH-211; JWH-212; JWH-213; JWH-234; JWH-235; JWH-236; JWH-239; JWH-240; JWH-241; JWH-258; JWH-262;
JWH-386; JWH-387; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400; JWH-412; JWH-413; JWH-414; JWH-415; JWH-424; AM-678; AM-1220; AM-1221;
AM-1235; AM-2232;
(b) Naphthylmethylindoles. Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring
by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent
and whether or not substituted in the naphthyl ring to any extent.
Some trade or other names: JWH-175; JWH-184; JWH-185; JWH-192; JWH-194;
JWH-195; JWH-196; JWH-197; JWH-199;
(c) Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure
with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or
not further substituted in the indole ring to any extent and whether or not
substituted in the phenyl ring to any extent.
Some trade or other names: 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole
(SR-18); 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8); 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250); 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203); JWH-167; JWH-201; JWH-202;JWH-204;
JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-237; JWH-248; JWH-249; JWH-251; JWH-253; JWH-302; JWH-303; JWH-304; JWH-305; JWH-306;
JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-316;
Cannabipiperidiethanone;
(d) Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with
substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further
substituted in the indole ring to any extent and whether or not substituted in the
phenyl ring to any extent.
Some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline (WIN 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4); AM-630; AM-661; AM-2233;
AM-1241;
(e) Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure
with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further
substituted in the pyrrole ring to any extent and whether or not substituted in the
naphthyl ring to any extent.
Some trade or other names: JWH-307; JWH-030; JWH-031; JWH-145; JWH-146;
JWH-147; JWH-150; JWH-156; JWH-242; JWH-243; JWH-244; JWH-245; JWH-246; JWH-292; JWH-293; JWH-308; JWH-309; JWH-346; JWH-348; JWH-363;
JWH-364; JWH-365; JWH-367; JWH-368; JWH-369; JWH-370; JWH-371; JWH-373; JWH-392;
(f) Naphthylmethylindenes. Any compound containing a naphthylideneindene
structure with substitution at the 3-position of the indene ring by an alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent
and whether or not substituted in the naphthyl ring to any extent.
Some trade or other names: JWH-171; JWH-176; JWH-220;
(g) Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol
structure with substitution at the 5-position of the phenolic ring by an alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not substituted in the cyclohexyl ring to any extent.
Some trade or other names: 5-( 1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47, 497 and homologues, which includes C8);
cannabicyclohexanol; CP-55,490; CP-55,940; CP-56,667;
(h) (6aR,10aR)-9-(hydroxymethyl )-6,6-dimethyl-3-(2-methyloctan-2-yl) 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names: HU-210;
(i) 2,3-Dihydro-5-methyl-3-(4-m orpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenyl. Some trade or other names: WIN 55, 212-2;
(j) Substituted Acetylindoles. Any compound containing a 3-acetyl indole structure
substituted at the acetyl with a tetramethylcyclopropyl, adamantyl, or benzyl
substituent whether or not further substituted in the tetramethylcyclopropyl,
adamantyl, or benzyl substituent to any extent and whether or not further
substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether
or not further substituted in the indole ring to any extent.
Some trade and or names: (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144); (1-(5-fluoropentyl)indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11); (1-(2-morpholin-4-ylethyl)-
1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (A-796,260); 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole (AM-1248); 1-Pentyl-3-(1-adamantoyl)indole (AB-001 and JWH-018 adamantyl analog); AM-679;
(k) Substituted Carboxamide Indole. Any compound containing a 3-carboxamide
indole structure substituted at the carboxamide with a tetramethylcyclopropyl, or
adamantyl substituent, whether or not further substituted in the
tetramethylcyclopropyl, or adamantyl substituent to any extent and whether or not
further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,or (tetrahydropyran-4-yl)methyl group whether
or not further substituted in the indole ring to any extent.
Some trade and other names: JWH-018 adamantyl carboxamide; STS-135;
(47) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI);
(48) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(49) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
(50) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
(51) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
(52) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
(53) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
(54) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
(55) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); and
(56) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
(57) Substituted phenethylamine. Any compound, unless specifically exempt, listed as a
controlled substance in another schedule or an approved FDA drug , structurally derived
from phenylethan-2-amine by substitution on the phenyl ring in any of the following
ways, that is to say--by substitution with a fused methylenedioxy, fused furan, or fused
tetrahydrofuran ring system; by substitution with two alkoxy groups; by substitution with
one alkoxy and either one fused furan, tetrahydrofuran, or tetrahydropyran ring system;
by substitution with two fused ring systems from any combination of the furan,
tetrahydrofuran, or tetrahydropyran ring systems; whether or not the compound is further
modified in any of the following ways:
(a) By substitution on the phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl,
alkoxy, or alkylthio groups;
(b) By substitution on the 2-position by any alkyl groups; or
(c) By substitution on the 2-amino nitrogen atom with alkyl, dialkyl, benzyl,
methoxybenzyl, or hydroxybenzyl groups.
Some trade and other names: 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine
(2C-T or 4-methylthio-2,5-dimethoxyphenethylamine);
1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine (DOI or
2,5-Dimethoxy-4-iodoamphetamine);
1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB or
2,5-Dimethoxy-4-bromoamphetamine);
1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine (DOC or
2,5-Dimethoxy-4-chloroamphetamine);
2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
(2C-B-NBOMe; 25B-NBOMe or
2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine);
2-4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
(2C-B-NBOMe; 25B-NBOMe or
2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine);N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine (Mescaline-NBOMe or
3,4,5-trimethoxy-N-(2-methoxybenzyl)phenethylamine);
2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
(2C-C-NBOMe; 25C-NBOMe or
2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine);
2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine
(2CB-5-hemiFLY); 2-(8-bromo-2,3,6,7-tetrahydrofuro
[2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-FLY);
2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-yl)ethanamine
(2C-B-butterFLY);
N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane (2C-B-FLY-NBOMe);
1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine
(bromo-benzodifuranyl-isopropylamine or bromo-dragonFLY);
N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine (2C-I-NBOH or
25I-NBOH); 5-(2-Aminoprpyl)benzofuran (5-APB); 6-(2-Aminopropyl)benzofuran
(6-APB); 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
6-(2-Aminopropyl)-2,3,-dihydrobenzofuran (6-APDB);
(58) Substituted tryptamines. Any compound, unless specifically exempt, listed as a controlled
substance in another schedule or an approved FDA drug ,structurally derived from
2-(1H-indol-3-yl)ethanamine (i.e, tryptamine) by mono- or di-substitution of the amine
nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom in a
cyclic structure whether or not the compound is further substituted at the alpha-position
with an alkyl group or whether or not further substituted on the indole ring to any extent
with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups.
Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin);
4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
4-hydroxy-N,N-diisopropyltryptamine (4-HO-DIPT);
5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
(59) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB-13);
(60) N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide (AKB 48);
(61) 1-(4-Fluorophenyl)piperazine (pFPP);
(62) 1-(3-Chlorophenyl)piperazine (mCPP);
(63) 1-(4-Methoxyphenyl)piperazine (pMeOPP);
(64) 1,4-Dibenzylpiperazine (DBP);
(65) Isopentedrone;
(66) Fluoromethamphetamine;
(67) Fluoroamphetamine;
(68) Fluorococaine.
Section 5. That § 34-20B-25 be amended to read as follows:
34-20B-25. The following are included in Schedule IV:
(1) Chlordiazepoxide, but not including librax (chlordiazepoxide hydrochloride and
clindinium bromide) or menrium (chlordiazepoxide and water soluble esterified
estrogens);
(2) Clonazepam;
(3) Clorazepate;
(4) Diazepam;
(4A) Flunitrazepam;
(5) Flurazepam;
(6) Mebutamate;
(7) Oxazepam;
(8) Prazepam;
(9) Lorazepam;
(10) Triazolam;
(11) Any substance which contains any quantity of a benzodiazepine, or salt of
benzodiazepine, except those substances which are specifically listed in other schedules;
(12) Repealed by SL 2003, ch 183, § 4;
(13) Cathine;
(14) Fencamfamine;
(15) Fenproporex;
(16) Mefenorex;
(17) Pyrovalerone;
(18) Propoxyphene;
(19) Pentazocine;
(20) Diethylpropion;
(21) Ethchlorvynol;
(22) Ethinamate;
(23) Fenfluramine;
(24) Mazindol;
(25) Mephobarbital;
(26) Methohexitol;
(27) Paraldehyde;
(28) Pemoline;
(29) Petrichloral;
(30) Phentermine;
(31) Barbital;
(32) Phenobarbital;
(33) Meprobamate;
(34) Zolpidem;
(35) Butorphanol;
(36) Modafinil, including its salts, isomers, and salts of isomers;
(37) Sibutramine;
(38) Zaleplon;
(39) Dichloralphenazone;
(40) Zopiclone (also known as eszopiclone), including its salts, isomers, and salts of isomers;
(41) Pregabalin;
(42) Lacosamide;
(43) Fospropofol, including its salts, isomers, and salts of isomers;
(44) Clobazam;
(45) Carisoprodol, including its salts, isomers, and salts of isomers;
(46) Ezogabine,[N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester],
including its salts, isomers, and salts of isomers; and
(47) Lorcaserin, any material, compound, mixture, or preparation which contains any quantity
of the following substances, including its salts, isomers, and salts of isomers, whenever
the existence of such salts, isomers, and salts of isomers is possible.
Section 6. Whereas, this Act is necessary for the immediate preservation of the public peace,
health, or safety, an emergency is hereby declared to exist, and this Act shall be in full force and
effect from and after its passage and approval.
An Act to revise the controlled substance schedule and to declare an emergency.
=========================
I certify that the attached Act
originated in the
SENATE as Bill No. 68
____________________________
Secretary of the Senate
=========================
____________________________
President of the Senate
____________________________
Secretary of the Senate
____________________________
Speaker of the House
____________________________
Chief Clerk
Senate Bill No. 68
File No. ____
Chapter No. ______
|
|
=========================
Received at this Executive Office
this _____ day of _____________ ,
20____ at ____________ M.
By _________________________
for the Governor
=========================
The attached Act is hereby
approved this ________ day of
______________ , A.D., 20___
____________________________
Governor
=========================
STATE OF SOUTH DAKOTA,
ss.
Office of the Secretary of State
Filed ____________ , 20___
at _________ o'clock __ M.
____________________________
Secretary of State
By _________________________
Asst. Secretary of State
|